|
Encouraging studies are promoting the
use of silybin as a way to alter the cell
cycle of certain types of cancer. Silybin
is the most potent ingredient in silymarin,
the compound responsible for the health
benefits of milk thistle. Although studies
are ongoing, silymarin's role is promising.
Early reports show that silymarin affects
cancer cells by disrupting the signals
to multiply and invade healthy cells.
Silymarin may also:
Slow
the growth of cancer cells in breast,
cervical, and prostate cancer.
Reduce
the toxic effects of chemotherapy drugs.
Offer
protection to the kidneys when using Cyclosporine,
a drug diagnosed primarily to prevent
transplant rejection. This medication
is often used in the treatment of various
types
of cancer. (But, it may also affect cyclosporine's
effectiveness.)
Inhibit
the formation of blood vessels that surround
tissue in order to feed a malignant tumor,
known as angiogenesis.
In addition, silymarin has been known
to improve the efficiency of chemotherapy
drugs such as cisplatin and doxorubicin
in the fight against ovarian and breast
cancer. This research is ongoing, but
silymarin is beginning to garner respect
from the scientific community as a potential
weapon against cancer.
Since the process of extracting silymarin
from milk thistle was developed in the
1980s, it has been easier to produce supplements
that are more potent. Though milk thistle
has not been evaluated and approved by
the FDA, the most commonly recommended
dosage is 200 mg to 400 mg twice per day.
The herb can also be taken as a tea, but
most people who take milk thistle prefer
the supplement. If you prefer the tea,
the dosage is 12 to 15 grams of the dried
herb infused in warm water.
Check with your healthcare professional
before adding milk thistle to your diet,
since there is a risk of severe allergic
reactions in people with an allergy to
flowers such as ragweed, marigolds and
artichokes. Pregnant women and children
should avoid milk thistle since its effect
on this population has not been confirmed
as safe for this population.
|